We want to congratulate the Seer team on their IPO, the next step on their journey to build an important new company in the proteomics field, enabling scientists and clinicians to ask questions about biological functions in ways that have never been possible before. To learn more about this exciting new technology and the suite of products being developed and commercialized, please visit www.seer.bio.

The views expressed herein are solely the views of the author(s) and are not necessarily the views of Maverick Capital, Ltd. or any of its affiliates. They are not intended to provide, and should not be relied upon for, investment advice.